페니트리움바이오 사업보고서 (2024.12)
1. 요약재무정보

1) 요약연결재무정보(단위: 원)

구분	제23기 당기말 (2024년 12월말)	제22기 전기말 (2023년 12월말)	제21기 전전기말 (2022년 12월말)

[유동자산]	11,318,540,872	25,555,266,153	40,589,451,279

ㆍ현금및현금성자산	5,778,521,189	3,372,575,210	3,097,124,698

ㆍ단기금융상품	64,639,019	15,601,000,000	24,000,000,000

ㆍ당기손익-공정가치측정금융자산	-	-	7,972,804,866

ㆍ매출채권및기타채권	4,116,556,662	4,829,834,701	3,985,136,066

ㆍ재고자산	-	1,162,854,413	402,481,233

ㆍ기타유동자산	1,358,824,002	589,001,829	1,131,904,416

[비유동자산]	17,208,079,755	18,658,927,574	5,702,953,933

ㆍ관계기업투자주식	1,021,295,668	871,971,044	952,060,316

ㆍ당기손익-공정가치측정비유동금융자산	1,019,373,400	974,520,000	224,364,912

ㆍ유형자산	1,727,936,655	2,849,220,036	2,792,157,646

ㆍ무형자산	235,560,683	1,081,519,184	973,401,615

ㆍ투자부동산	11,512,959,159	11,720,483,348	-

ㆍ기타비유동자산	1,690,954,190	1,161,213,962	760,969,444

자산총계	28,526,620,627	44,214,193,727	46,292,405,212

[유동부채]	20,544,553,253	15,296,655,852	14,207,021,960

[비유동부채]	1,353,558,150	1,789,955,526	1,375,585,374

부채 총계	21,898,111,403	17,086,611,378	15,582,607,334

지배기업소유주지분	6,822,017,441	27,150,789,792	30,340,609,792

[자본금]	4,298,917,900	2,183,625,000	2,183,625,000

[자본잉여금]	18,309,103,532	20,418,648,438	20,418,648,438

[기타자본]	(3,720,774,138)	(3,727,813,651)	(3,723,279,478)

[이익잉여금]	(12,065,229,853)	8,276,330,005	11,461,615,832

비지배지분	(193,508,217)	(23,207,443)	369,188,086

자본 총계	6,628,509,224	27,127,582,349	30,709,797,878

관계기업 투자주식의 평가방법	지분법	지분법	지분법

2024.01.01~2024.12.31	2023.01.01~2023.12.31	2022.01.01~2022.12.31

매출액	9,744,986,676	13,790,195,699	14,882,555,787

영업이익	(15,932,446,161)	(1,911,004,834)	(754,740,449)

당기순이익	(20,260,475,756)	(3,363,294,388)	(58,882,743)

지배기업소유주지분	(20,095,955,935)	(2,970,313,225)	266,502,935

비지배지분	(164,519,821)	(392,981,163)	(325,385,678)

주당순이익	(475)	(70)	12

희석주당이익	(475)	(70)	3

2) 요약재무정보(단위: 원)

구분	제23기 당기말 (2024년 12월말)	제22기 전기말 (2023년 12월말)	제21기 전전기말 (2022년 12월말)

[유동자산]	11,318,540,872	26,416,763,716	39,845,619,438

ㆍ현금및현금성자산	5,778,498,700	3,326,420,831	3,084,101,544

ㆍ단기금융상품	64,639,019	15,601,000,000	24,000,000,000

ㆍ당기손익-공정가치측정금융자산	-	-	7,972,804,866

ㆍ매출채권및기타채권	4,116,587,551	6,775,291,022	3,726,662,122

ㆍ기타유동자산	1,358,815,602	714,051,863	1,062,050,906

[비유동자산]	16,930,557,707	18,179,783,943	7,078,266,068

ㆍ당기손익-공정가치측정비유동금융자산	1,019,373,400	974,520,000	224,364,912

ㆍ종속기업투자주식	-	1,907,636,272	3,815,272,544

ㆍ관계기업투자주식	743,773,620	743,773,620	743,773,620

ㆍ유형자산	1,727,936,655	1,368,990,257	1,461,088,871

ㆍ무형자산	235,560,683	266,663,505	64,383,068

ㆍ투자부동산	11,512,959,159	11,720,483,348	-

ㆍ기타비유동자산	1,690,954,190	1,197,716,941	769,383,053

자산총계	28,249,098,579	44,596,547,659	46,923,885,506

[유동부채]	20,544,553,253	15,144,738,418	13,934,446,459

[비유동부채]	1,353,558,150	661,875,854	182,535,087

부채 총계	21,898,111,403	15,806,614,272	14,116,981,546

[자본금]	4,298,917,900	2,183,625,000	2,183,625,000

[자본잉여금]	19,271,975,315	21,395,991,395	21,395,991,395

[기타자본]	(3,675,175,357)	(3,739,155,755)	(3,739,155,755)

[이익잉여금]	(13,544,730,682)	8,949,472,747	12,966,443,320

자본 총계	6,350,987,176	28,789,933,387	32,806,903,960

종속,관계투자주식의 평가방법	원가법	원가법	원가법

2024.01.01~2024.12.31	2023.01.01~2023.12.31	2022.01.01~2022.12.31

매출액	9,744,986,676	13,790,195,699	14,881,305,787

영업이익	(15,932,446,161)	(1,911,004,834)	516,521,349

당기순이익	(22,223,140,160)	(3,800,188,519)	1,144,040,937

주당순이익	(525)	(90)	53

희석주당이익	(525)	(90)	42